Cargando…
Characteristics and Outcomes of Heart Transplant Recipients with Coronavirus-19 Disease
PURPOSE: Heart transplant(HT) recipients with SARS-CoV-2 infection may be at high risk of developing critical illness. The aim was to describe the characteristics and clinical outcomes of HT recipients with coronavirus-19 disease(COVID-19). METHODS: We prospectively included all adult HT recipients...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979373/ http://dx.doi.org/10.1016/j.healun.2021.01.1783 |
_version_ | 1783667270288932864 |
---|---|
author | Marcondes-Braga, F.G. Murad, C.M. Belfort, D. d. Dantas, R.C. Lira, M.S. Aragão, C. Siciliano, R.F. Mangini, S. Seguro, L. de Campos, I.W. Ávila, M.S. Bello, M.V. Barone, F. Strabelli, T.M. Gaiotto, F.A. Bacal, F. |
author_facet | Marcondes-Braga, F.G. Murad, C.M. Belfort, D. d. Dantas, R.C. Lira, M.S. Aragão, C. Siciliano, R.F. Mangini, S. Seguro, L. de Campos, I.W. Ávila, M.S. Bello, M.V. Barone, F. Strabelli, T.M. Gaiotto, F.A. Bacal, F. |
author_sort | Marcondes-Braga, F.G. |
collection | PubMed |
description | PURPOSE: Heart transplant(HT) recipients with SARS-CoV-2 infection may be at high risk of developing critical illness. The aim was to describe the characteristics and clinical outcomes of HT recipients with coronavirus-19 disease(COVID-19). METHODS: We prospectively included all adult HT recipients who received the diagnosis of COVID-19 in our institution. Inclusion criteria were one or more clinical symptoms of SARS-CoV-2 infection in the previous seven days and positive SARS-CoV-2 RT-PCR in nasopharyngeal samples. The enrollment was carried out from April to June, 2020. Demographic features, clinical characteristics, modes of transmission, laboratory data and other known prognosis markers at admission and through follow up were recorded. Patients were categorized according to the ordinal scale developed by WHO Committee. Outcomes and follow up were recorded until Aug/2020. RESULTS: Twenty-one HT recipients were included, most of them were men (57%); with median age of 48 years old and median HT time of 12 mo. The majority needed hospitalization. Immunosuppressive therapy was reduced or withdrawn in the majority of patients, except from steroids. Ten patients were classified as having severe disease according to WHO Committee scale. Lymphopenia was an independent predictor of severe disease and absolute lymphocyte count <416/mm(3) had 82% of sensitivity and 90% of specificity to define severe disease. Thirty-day mortality was 14%, similar to previously reported in other solid-organ transplant (SOT) cohorts. However, a longer follow up revealed increased 60-day mortality (33%) due to nosocomial infection. CONCLUSION: In this case series of HT recipients with COVID-19, the 30-day mortality rate was similar to that previously reported in SOT recipient's cohorts, but a longer follow up revealed increased later mortality related to long in-hospital stay. Further, lymphopenia was associated with severe disease and worse prognosis. These findings suggest the need for strict long-term follow up of these patients. |
format | Online Article Text |
id | pubmed-7979373 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79793732021-03-23 Characteristics and Outcomes of Heart Transplant Recipients with Coronavirus-19 Disease Marcondes-Braga, F.G. Murad, C.M. Belfort, D. d. Dantas, R.C. Lira, M.S. Aragão, C. Siciliano, R.F. Mangini, S. Seguro, L. de Campos, I.W. Ávila, M.S. Bello, M.V. Barone, F. Strabelli, T.M. Gaiotto, F.A. Bacal, F. J Heart Lung Transplant (19) PURPOSE: Heart transplant(HT) recipients with SARS-CoV-2 infection may be at high risk of developing critical illness. The aim was to describe the characteristics and clinical outcomes of HT recipients with coronavirus-19 disease(COVID-19). METHODS: We prospectively included all adult HT recipients who received the diagnosis of COVID-19 in our institution. Inclusion criteria were one or more clinical symptoms of SARS-CoV-2 infection in the previous seven days and positive SARS-CoV-2 RT-PCR in nasopharyngeal samples. The enrollment was carried out from April to June, 2020. Demographic features, clinical characteristics, modes of transmission, laboratory data and other known prognosis markers at admission and through follow up were recorded. Patients were categorized according to the ordinal scale developed by WHO Committee. Outcomes and follow up were recorded until Aug/2020. RESULTS: Twenty-one HT recipients were included, most of them were men (57%); with median age of 48 years old and median HT time of 12 mo. The majority needed hospitalization. Immunosuppressive therapy was reduced or withdrawn in the majority of patients, except from steroids. Ten patients were classified as having severe disease according to WHO Committee scale. Lymphopenia was an independent predictor of severe disease and absolute lymphocyte count <416/mm(3) had 82% of sensitivity and 90% of specificity to define severe disease. Thirty-day mortality was 14%, similar to previously reported in other solid-organ transplant (SOT) cohorts. However, a longer follow up revealed increased 60-day mortality (33%) due to nosocomial infection. CONCLUSION: In this case series of HT recipients with COVID-19, the 30-day mortality rate was similar to that previously reported in SOT recipient's cohorts, but a longer follow up revealed increased later mortality related to long in-hospital stay. Further, lymphopenia was associated with severe disease and worse prognosis. These findings suggest the need for strict long-term follow up of these patients. Published by Elsevier Inc. 2021-04 2021-03-20 /pmc/articles/PMC7979373/ http://dx.doi.org/10.1016/j.healun.2021.01.1783 Text en Copyright © 2021 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | (19) Marcondes-Braga, F.G. Murad, C.M. Belfort, D. d. Dantas, R.C. Lira, M.S. Aragão, C. Siciliano, R.F. Mangini, S. Seguro, L. de Campos, I.W. Ávila, M.S. Bello, M.V. Barone, F. Strabelli, T.M. Gaiotto, F.A. Bacal, F. Characteristics and Outcomes of Heart Transplant Recipients with Coronavirus-19 Disease |
title | Characteristics and Outcomes of Heart Transplant Recipients with Coronavirus-19 Disease |
title_full | Characteristics and Outcomes of Heart Transplant Recipients with Coronavirus-19 Disease |
title_fullStr | Characteristics and Outcomes of Heart Transplant Recipients with Coronavirus-19 Disease |
title_full_unstemmed | Characteristics and Outcomes of Heart Transplant Recipients with Coronavirus-19 Disease |
title_short | Characteristics and Outcomes of Heart Transplant Recipients with Coronavirus-19 Disease |
title_sort | characteristics and outcomes of heart transplant recipients with coronavirus-19 disease |
topic | (19) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979373/ http://dx.doi.org/10.1016/j.healun.2021.01.1783 |
work_keys_str_mv | AT marcondesbragafg characteristicsandoutcomesofhearttransplantrecipientswithcoronavirus19disease AT muradcm characteristicsandoutcomesofhearttransplantrecipientswithcoronavirus19disease AT belfortdd characteristicsandoutcomesofhearttransplantrecipientswithcoronavirus19disease AT dantasrc characteristicsandoutcomesofhearttransplantrecipientswithcoronavirus19disease AT lirams characteristicsandoutcomesofhearttransplantrecipientswithcoronavirus19disease AT aragaoc characteristicsandoutcomesofhearttransplantrecipientswithcoronavirus19disease AT sicilianorf characteristicsandoutcomesofhearttransplantrecipientswithcoronavirus19disease AT manginis characteristicsandoutcomesofhearttransplantrecipientswithcoronavirus19disease AT segurol characteristicsandoutcomesofhearttransplantrecipientswithcoronavirus19disease AT decamposiw characteristicsandoutcomesofhearttransplantrecipientswithcoronavirus19disease AT avilams characteristicsandoutcomesofhearttransplantrecipientswithcoronavirus19disease AT bellomv characteristicsandoutcomesofhearttransplantrecipientswithcoronavirus19disease AT baronef characteristicsandoutcomesofhearttransplantrecipientswithcoronavirus19disease AT strabellitm characteristicsandoutcomesofhearttransplantrecipientswithcoronavirus19disease AT gaiottofa characteristicsandoutcomesofhearttransplantrecipientswithcoronavirus19disease AT bacalf characteristicsandoutcomesofhearttransplantrecipientswithcoronavirus19disease |